Market Cap Increases by 3 Trillion Won in a Day: What Happened to Genetic Testing Stock Natera?

Natera Inc. (NASDAQ: NTRA) closed at $220 on the Nasdaq on the 5th, up 6.40% from the previous day. On that day, the company’s market capitalization increased by approximately $2.1 billion (about 3 trillion KRW), bringing its total market cap to around $31.1 billion (roughly 44 trillion KRW). Trading volume was about 1.49 million shares.

According to recent regulatory filings, co-founder and director Jonathan Sheena and president John Pesco have each sold stakes worth tens of thousands of dollars, reflecting a series of small insider sales. Additionally, Natera has alleviated some of its intellectual property risk after securing a U.S. District Court for the District of Delaware ruling in its patent litigation against competitor Invitae, entitling Natera to ongoing royalties equal to 30% of related future revenue.

Headquartered in Austin, Texas, Natera is a clinical genetic testing company that offers cell-free DNA–based noninvasive tests primarily in the areas of women’s health, oncology, and organ transplantation. Its flagship products include the Panorama prenatal screening test, Signatera for tracking minimal residual disease, and Prospera for monitoring transplant rejection. Natera continues to expand its market share in the U.S. precision medicine and genetic diagnostics sector.